期刊文献+

齐拉西酮的血药浓度与其治疗精神分裂症疗效的相关性分析 被引量:7

Correlation between plasma concentration and clinical efficacy of ziprasidone
下载PDF
导出
摘要 目的探讨齐拉西酮在中国精神分裂症患者体内的血药浓度与临床疗效的关系。方法采用超高效液相色谱-质谱联用(UPLC-MS/MS)的方法测定41例精神分裂症患者体内齐拉西酮的血浆药物浓度,疗效评定采用阳性与阴性症状量表(PANSS)评分,用SPSS 13.0统计软件包对血药浓度与疗效评分进行统计分析。结果治疗1、2、3、4周末的齐拉西酮血药峰浓度与1、2、3、4周末的PANSS减分率无相关性,而3、4周末的平均稳态谷浓度与4周末的PANSS减分率呈正相关(P<0.05)。同时,将稳态血-药谷浓度分为小于110.0 ng.mL-1组和大于110.0 ng.mL-1组患者的疗效进行比较,结果前者的PANSS减分率明显低于后者,两者差异有统计学意义(P<0.05)。结论根据本实验研究结果,初步得出齐拉西酮的临床疗效与其稳态谷浓度高低有关,其稳态谷浓度>110.0 ng.mL-1时,疗效较好。 Objective To determine the relationship between plasma concentration and clinical efficacy of ziprasidone in Chinese schizophrenics.Methods Ziprasidone plasma sample concentrations were determined by UPLC-MS/MS.Efficacy was measured by the positive and negative syndrome scale(PANSS)scores,and the relationship between plasma concentration and clinical efficacy of ziprasidone was analyzed by SPSS 13.0.Results The peak concentrations of aripiprazole on weekend 1,2,3,and 4 did not correlate with the decreased ratios of PANSS scores,which were positively correlated with the average steady state trough concentrations of ziprasidone on weekend 3 and 4(P〈0.05).The PANSS scores at above 110.0 ng·mL-1 decreased significantly compared with the lower concentration(P〈0.05).Conclusion The steady state trough concentrations of ziprasidone are correlative with the efficacy scores,with better results above 110.0 ng·mL-1.
出处 《中南药学》 CAS 2010年第11期847-851,共5页 Central South Pharmacy
关键词 齐拉西酮 精神分裂症 药物评价 血浆药物浓度 临床疗效 相关性检验 ziprasidone; schizophrenia; drug evaluation; plasma drug level; clinical efficacy; correlation test
  • 相关文献

参考文献15

  • 1Caley CF,Cooper CK.Ziprasidone:the fifth atypical antipsychotic[J].Ann Pharmacother,2002,36(5):839-851.
  • 2Seeger TF,Seymour PA,Schrnidt AW,et al,Ziprasidone(CP-88059):a new antipsychotic with combined dopamine and serotonin receptor antagonist activity[J].J Pharmacol Exp Ther,1995,275(1):101-113.
  • 3Rollerna H,Lu Y,Schmidt AW,et al.5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex[J].Biol Psychiatry,2000,48(2):229-237.
  • 4Seeger TF,Seymour PA,Schmidt AW,et al.Ziprasidone(CP-88,059):a new antipsychotic with combined doparnine and serotonin receptor antagonist activity[J].J Pharrnacol Exp Ther,1995,275(1):101-113.
  • 5中华医学会精神科分会.中国精神障碍分类与诊断标准第3(CCMD-3)[M].济南:山东科学技术出版社,2001:75-78.
  • 6Huang PC,Yu SL,Lin YM,et al.Body weight of Chinese adults by sex,age and body height and criterion of obesity based on body mass index[J].Nutr Sci J,1992,17(2):157-172.
  • 7Lei YQ,Zhang WY,Li HD,et al.Determination of ziprasidone by UPLC-MS-MS and its application to a pharmacokinetic study of Chinese Schizophrenics I-J3.Chrornatographia,2010,72(9):975-979.
  • 8Zorn SH,Lebel LA,Schmidt AW,et al.Pharmacological and neurochemical studies with the new antipsychotic ziprasidone.In:Palomo T,Beninger R,Archer T,editors.Interactive monoaminergic basis of brain disorders[M].Madrid:Fundacion Cerebro y Mente,1999:377-393.
  • 9Altar CA,Wasley AM,Neale RF,et al.Typical and atypical antipsychotic occupancy of D2 and S2 receptors:an autoradiographic analysis in rat brain[J].Brain Res Bull,1986,16(4):517-525.
  • 10Bersani G,Grispini A,Marini S,et aL Neuroleptic-induced extrapyramidal side effects:clinical perspectives with ritanserin (R 55667),a newselective 5-HT2 receptor blocking agent[J].Curr Ther Res,1986,40(3):492-9.

同被引文献71

引证文献7

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部